Imagine some tumors are like frozen fortresses that the body's immune system can't enter. This technology uses a modified virus to 'melt' that ice and lure immune cells inside. Once the fortress is open, standard cancer drugs can finally get in and destroy the tumor from the inside out.
70-90% of cancer patients do not respond to immune checkpoint inhibitors because their tumors are 'cold' and lack the necessary immune cells to trigger a response.
A clinical-stage oncolytic adenovirus (TILT-123) armed with TNF alpha and IL-2 cytokines, supported by Phase 1 safety and dosing data.
If you are a drug developer dealing with the 70-90% of patients who don't respond to immune checkpoint inhibitors — this project developed TILT-123 that 'heats up' cold tumors to make those drugs work.
If you are a clinical trial manager dealing with the need for Phase 2 trial designs for refractory cancers — this project developed a validated dosing and safety profile for TILT-123 in over 50 patients.
If you are a clinic dealing with patients with advanced ovarian, lung, or head and neck cancers who have failed other treatments — this project developed an intravenous oncolytic immunotherapy to provide a new curative option.
Based on available project data, the specific cost per dose or pricing strategy for TILT-123 is not disclosed.
Based on available project data, the project focused on Phase 1b clinical trials and regulatory strategy; specific industrial manufacturing scale-up details are not provided.
The technology is based on TILT Biotherapeutics' proprietary oncolytic viruses. The project objective explicitly mentions securing a global pharmaceutical customer to take the asset to market.
The project completed Phase 1 dose escalation and organized regulatory workshops to prepare for Phase 2, with a Phase 1b study in ovarian cancer ready to start.
The specific EU-funded project period lasted from 2022-07-01 to 2023-12-31.
The project is led by a single partner, TILT Biotherapeutics Oy, a Finnish SME. This 100% industry-led structure indicates a high level of commercial drive and a streamlined decision-making process, as the company is already at a clinical stage and seeking a global pharmaceutical partner for market entry.
Contact TILT Biotherapeutics Oy in Finland regarding TILT-123 licensing.
Connect with TILT Biotherapeutics to discuss Phase 2 partnership opportunities.
